Procter & Gamble Co

A volatile end to 2018 resulted in an overly conservative positioning going into 2019.

Value funds plus big upgrades are worth a look.

We are maintaining our $106 FVE.

We believe investors should await a more favorable entry point before buying shares of this wide-moat firm.

Fourth-quarter earnings announcements from financial, consumer products, and technology sectors.

A fund that shouldn’t succeed, but does.

This strategy effectively targets firms that should have the capacity to raise their dividends in the future.

Wide-moat Procter & Gamble chalked up another quarter of strong sales and profit gains.

Concerns over the valuations of this fund's holdings are overblown.

We like what we're seeing from the wide-moat firm but think it's overvalued.

The menu of dividend ETFs features something for every palate.

Plus, the 10 cheapest names in the index today.

A visual take on the term.

Seven of the top 10 dividend-yielding names are undervalued.

How did funds hold up in a nasty quarter?

These wide-moat, low uncertainty names may be slightly overpriced today, but they should be on quality seekers’ watchlists.

These three funds delivered in 2018 but had sizable outflows.

Several cases can be made for buying what seem to be fairly valued high-quality stocks.

We examine Gold-rated ETFs, new investment themes, and the debt ceiling on this week's episode.

Organic sales jumped 4% in the quarter, and the wide-moat firm remains fairly valued.